Which stocks are expected to attract attention on November 18? Shares of Ashoka Buildcon, Prestige Estate Projects, Glenmark Pharmaceuticals, HCLTech, Signature Global, Prime Focus, and Indian Metals & Ferro Alloys (IMFA) are in focus due to recent announcements involving major projects, acquisitions, and partnerships.
- Ashoka Buildcon won a ₹1,465-crore project from the National Highways Authority of India (NHAI).
- Prestige Estate Projects acquired a 50% stake in Advent Convention and Hotels International.
- Signature Global-led consortium acquired 475 acres of land in Maharashtra.
- Glenmark Pharmaceuticals submitted an IND application for a new cancer drug.
- Prime Focus's group company partnered with Meta for 3D movie content.
- HCLTech formed a strategic AI partnership with Canadian firm Cohere.
- IMFA started production from its second furnace in Odisha.
What major project did Ashoka Buildcon secure?
Ashoka Buildcon emerged as the lowest bidder for a ₹1,465-crore project awarded by the National Highways Authority of India (NHAI). This project involves completing an eight-lane, access-controlled section of the Vadodara-Mumbai Expressway in Gujarat, specifically the Jujuwa-Gandeva stretch (Package VIII). The work will be carried out on an Engineering, Procurement and Construction (EPC) basis with an 18-month completion timeline and a 10-year defect liability period.
What acquisition did Prestige Estate Projects announce?
Prestige Estate Projects' wholly owned subsidiary, Prestige Falcon Realty Ventures Pvt Ltd, acquired a 50% stake in Advent Convention and Hotels International Pvt Ltd. The acquisition involved subscribing to 2,695,970 equity shares, expanding Prestige's presence in the hospitality sector.
How is Signature Global expanding beyond Delhi-NCR?
Signature Global, through a consortium led by its subsidiary Maa Vaishno Net-Tech Ltd, won a bid to acquire 474.66 acres of land in Raigad, Maharashtra, for ₹194.19 crore. Signature Global will hold a 65% stake in the special purpose vehicle owning the land. This follows their earlier acquisition of 194 acres in Gurugram for a luxury housing project expected to generate ₹6,000 crore in revenue.
What new drug development is Glenmark Pharmaceuticals pursuing?
Glenmark Pharmaceuticals’ subsidiary, Ichnos Glenmark Innovation (IGI), submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for ISB 2301. This investigational multispecific immune cell activator targets solid tumors by engaging T cells and natural killer cells to activate the immune system. A Phase 1 clinical trial is planned for 2027.
What partnership did Prime Focus announce?
Prime Focus's group company DNEG announced a technology partnership with Meta to create a catalogue of popular movie titles in stereo 3D for Meta VR Glasses, set to launch in spring 2027. The catalogue will include titles like "The Hunger Games: Sunrise on the Reaping," converted in collaboration with Meta and Lionsgate.
What is the focus of HCLTech's new AI partnership?
HCLTech partnered with Canadian AI company Cohere to develop sovereign AI solutions for enterprises and governments. HCLTech will be a preferred global systems integrator in Canada and Germany, focusing initially on insurance, financial services, and manufacturing sectors. The collaboration combines Cohere's AI platform with HCLTech's technology services to address data security and regulatory compliance.
What recent production milestone did Indian Metals & Ferro Alloys (IMFA) achieve?
IMFA commenced the first tapping of hot metal from the second furnace at its greenfield ferro chrome expansion project in Kalinganagar, Odisha, on November 17, 2026. Production from this furnace will gradually increase. The company started hot metal tapping from the first furnace on August 25, 2026.
The domestic equity market is expected to open lower on November 18, with GIFT NIFTY futures indicating the NIFTY50 index may open 167 points down. Investors should monitor these developments closely.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Readers should consult a financial advisor before making investment decisions.

